Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pre-DLI Salvage Chemotherapy-Washington University School of Medicine-acute myeloid leukemia-myelodysplastic syndromes
- Development stage
- Unknown
- Lead developer
- Washington University School of Medicine
- Modality
- Cell Therapies, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
This treatment regimen refers to a Phase I clinical trial protocol (NCT02461927) developed by Washington University School of Medicine for patients with relapsed acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) following an allogeneic stem cell transplant. The protocol evaluates the safety and feasibility of a sequential therapy consisting of salvage chemotherapy (administered at the physician's discretion), followed by a donor lymphocyte infusion (DLI), and subsequent cycles of azacitidine. Azacitidine, a hypomethylating agent, is utilized in this context to potentially modulate T-cell function and reduce the incidence of graft-versus-host disease (GVHD) while maintaining the graft-versus-leukemia (GVL) effect provided by the DLI.
- Other names
- Azacitidine After DLI for Relapsed AML/MDS Post-Transplant
Beyond the preview
Go deeper on Pre-DLI Salvage Chemotherapy-Washington University School of Medicine-acute myeloid leukemia-myelodysplastic syndromes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pre-DLI Salvage Chemotherapy-Washington University School of Medicine-acute myeloid leukemia-myelodysplastic syndromes.